In a 1,000-page document sent to the FDA, American Gene Technologies (AGT) outline what they say could be the cure for HIV/AIDS. The research facility is based in Maryland, and submitted their research for Phase I trial of its autologous cell therapy for HIV.
The innovative HIV treatment which AGT have been developing uses immunotherapy which CEO Jeff Galvin says, “If we are successful, patients will be able to throw away their medication, will not progress to AIDS, and will be immune to future HIV exposures.”
This unique approach isolates the key immune cells which provide immunity against viruses and protects them from HIV which quickly disables them. If achieved, the cell’s will no longer be disabled by the present HIV and will prevent any future rise.
AGT should hear whether they can proceed with clinical trials by the end of year/start of 2020.